drugset / Trial / NCT02021422

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

NCT02021422

Phase 1 Completed 13 enrolled Baylor Research Institute
NaSingle-groupOpen-labelTreatment

Summary

The study's overall objectives are to evaluate the safety of anakinra in combination with standard chemotherapy regimens in patients with pancreatic ductal adenocarinoma, as well as to collect preliminary immune modulation and clinical activity information, overall survival, and serious adverse events related to the study drug.

Timeline

Start
2013-12
Primary completion
2017-12
Completion
2021-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Anakinra Protein / enzyme biologic 100 mg Subcutaneous
Background Irinotecan Small molecule 180 mg/m2
Background Oxaliplatin Small molecule 85 mg/m2
Background fluorouracil Small molecule 2400 mg/m2